Clinical Pharmacy

CP-166

QUALITY PERCEIVED BY THE PATIENTS OF A PHARMACEUTICAL CARE CONSULTATION AND STEPS TAKEN TO IMPROVE IT

CP-163

ANALYSIS OF THE SIDE EFFECTS AND THE TREATMENT DISCONTINUATION OF DIMETHYL FUMARATE IN A TERTIARY HOSPITAL

CP-161

INCIDENCE OF ABNORMALITIES OF URINARY DIPSTICK TESTS IN PATIENTS RECEIVING BIOTHERAPIES

CP-160

CLINICAL PHARMACIST INTERVENTIONS IN THE CRITICAL PATIENT: EVOLUTION OF A 4 YEAR PROJECT

CP-159

DIRECT ACTING ANTIVIRALS (DAAS) FOR THE TREATMENT OF HCV INFECTION IN HIV/HCV COINFECTED PATIENTS: A CLINICAL EXPERIENCE

CP-158

UNCRITICAL USE OF PROTON PUMP INHIBITORS IN NON-INTENSIVE CARE UNITS OF A UNIVERSITY HOSPITAL

CP-157

ANALYSIS OF THE EXPENDITURE ON THE TREATMENT OF HEPATITIS C VIRUS IN 2015

CP-1566

PRESCRIBING PATTERN, TOLERABILITY AND EFFICACY STUDY (4 WEEKS) OF THE NOVEL DRUG ‘XIAPEX’

CP-155

USE AND SAFETY PROFILE OF ORAL MEDICATION BEFORE SECONDLINE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

CP-154

ACUTE CORONARY SYNDROME IN A PATIENT RECEIVING ROMIPLOSTIM

CP-152

APPLYING THE RESULTS FROM THE TOGA TRIAL INTO CLINICAL PRACTICE: DATA FROM THE AGAMENON MULTICENTRE STUDY

CP-149

REDESIGN OF THE MANAGEMENT MODEL AND PHARMACEUTICAL CARE OF PATIENTS WITH HEPATITIS C VIRUS INFECTION

CP-148

IMPACT ON DRUG ADHERENCE AND VIRAL LOAD AFTER PHARMACEUTICAL INTERVENTION IN SELECTED HEPATITIS B OUTPATIENTS

CP-146

DRUG INTERACTIONS WITH DIRECT ACTING ANTIVIRALS FOR HEPATITIS C: WHAT ABOUT IN PRACTICE? PHARMACEUTICAL IMPACT

CP-143

THE CHANGE IN USE OF CALCINEURIN INHIBITORS IN KIDNEY TRANSPLANT RECIPIENTS AND ITS EFFECT ON SHORT TERM GRAFT AND PATIENT OUTCOMES

Pages